RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2022
Top Holdings96 positions
ASCENDIS PHARMA A/S | 7.6M | $888.2M | 19.4% | $95.96 | +20.90% | 14 qtrssince 2018-Q4 | Unchanged 0 |
BIOGEN INC | 727,024 | $153.1M | 3.3% | $211.03 | 0.00% | 1 qtr | New 84 |
| 8.3M | $151.5M | 3.3% | — | — | 4 qtrssince 2021-Q2 | Unchanged 0 | |
CYTEK BIOSCIENCES INC | 13.4M | $144.2M | 3.1% | $18.15 | -39.44% | 3 qtrssince 2021-Q3 | Increased 73 |
ITEOS THERAPEUTICS INC | 4.4M | $142.1M | 3.1% | — | — | 7 qtrssince 2020-Q3 | Unchanged 0 |
TRAVERE THERAPEUTICS INC | 4.9M | $126.9M | 2.8% | $26.83 | -3.93% | 6 qtrssince 2020-Q4 | Decreased 0 |
JANUX THERAPEUTICS INC | 8.7M | $124.3M | 2.7% | $25.37 | -42.57% | 4 qtrssince 2021-Q2 | Unchanged 0 |
VAXCYTE INC | 4.6M | $110.6M | 2.4% | $29.78 | -19.17% | 8 qtrssince 2020-Q2 | Increased 56 |
ELIEM THERAPEUTICS INC | 13.2M | $110.3M | 2.4% | $17.23 | -51.42% | 3 qtrssince 2021-Q3 | Unchanged 0 |
IMMUNOGEN INC | 21.7M | $103.5M | 2.3% | — | — | 7 qtrssince 2020-Q3 | Increased 55 |
DICE THERAPEUTICS INC | 5.2M | $99.6M | 2.2% | — | — | 3 qtrssince 2021-Q3 | Unchanged 0 |
GH RESEARCH PLC | 4.8M | $88.3M | 1.9% | $19.84 | -9.29% | 4 qtrssince 2021-Q2 | Increased 70 |
FORMA THERAPEUTICS HLDGS INC | 9M | $83.8M | 1.8% | — | — | 8 qtrssince 2020-Q2 | Unchanged 0 |
TYRA BIOSCIENCES INC | 7.2M | $77.4M | 1.7% | $16.91 | -39.03% | 3 qtrssince 2021-Q3 | Unchanged 0 |
POINT BIOPHARMA GLOBAL INC | 9M | $71.8M | 1.6% | — | — | 3 qtrssince 2021-Q3 | Unchanged 0 |
CELLDEX THERAPEUTICS INC NEW | 2.1M | $70.7M | 1.5% | $48.42 | -28.56% | 3 qtrssince 2021-Q3 | Increased 53 |
BELLUS HEALTH INC NEW | 10.2M | $70.4M | 1.5% | — | — | 2 qtrssince 2021-Q4 | Unchanged 0 |
ENANTA PHARMACEUTICALS INC | 964,212 | $68.6M | 1.5% | $69.22 | 0.00% | 1 qtr | New 68 |
VOR BIOPHARMA INC | 11.1M | $67.2M | 1.5% | $781.20 | -84.13% | 5 qtrssince 2021-Q1 | Unchanged 0 |
NKARTA INC | 5.6M | $63.8M | 1.4% | $30.36 | -62.38% | 7 qtrssince 2020-Q3 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $4.6B across 96 positions as of Q1 2022. Top holdings: ASND (19.4%), BIIB (3.3%), AEROVATE THERAPEUTICS INC (3.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2/5.0.
Active quarter - 10 new positions, 11 exits, 11 increased. Top move: BIIB (NEW, conviction 84). Portfolio: $4.6B across 96 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR